Antibody/Targeted-Drug Conjugates 2019

6-8 November 2019, Queen’s University Belfast, Belfast, Northern Ireland, UK

  • Increase font size
  • Default font size
  • Decrease font size


Join the conversation on Twitter – #ATDC2019

The concept of using biologics and particles including monoclonal antibodies to deliver drugs to disease targets such as cancer cells has been explored for decades, with early work surrounding non-specific targets and drugs with low potencies. These studies highlighted the importance of critical parameters, such as antigen and tumor target selection, linker stability, drug potency, pharmacokinetics and conjugation methodology, in developing effective targeted drug conjugates with acceptable safety/toxicity profiles.

The third ATDC New Developments & Updates conference to be held in Belfast, Northern Ireland, UK in November 2019 will aim to examine the concept and future of targeted drug delivery systems to include antibodies/bispecific antibodies/proteins/nanoparticles and other biologics.

The ATDC 2019 scientific programme will include keynote lectures, contributed papers and poster presentations emphasising all key aspects and recent developments surrounding targeted drug delivery systems.

Abstracts for oral and poster presentation are called for – please see the participation page for abstract submission details.

Scientific Advisory Panel

Conference Chairman:
Chris Scott (Queen’s University Belfast, Belfast, UK)

John A. Flygare (Merck Inc., USA)
Greg Bleck (Catalent Pharma Solutions, Somerset, New Jersey, USA)
Victor Goldmacher (Forbius Inc., Austin, Texas, USA)
Roger R. Beerli (NBE-Therapeutics LLC, Basel, Switzerland)
Michael Firer (Ariel University, Ariel, Israel)
Alain Beck (Centre d’Immunologie Pierre Fabre, St Julien-en-Genevois, France)
Philip Howard (MedImmune/Spirogen Ltd, London, UK)
Peter Hofland (InPress Media Group, Phoenix, Arizona, USA)
David Rabuka (Catalent Pharma Solutions, Somerset, New Jersey, USA)
Peter Park (Bicycle Therapeutics Inc., Cambridge, Massachusetts, USA)
Hendrik Jan Houthoff (LinXis Pharmaceuticals BV, Amsterdam, The Netherlands)
Deyarina Gonzalez (Swansea University Medical School, Swansea, Wales, UK)
Steve Conlan (Swansea University Medical School, Swansea, Wales, UK)
Ulrich Storz (Michalski Hattermann & Partners, Dusseldorf, Germany)
Aad van de Leur (Synthon Biopharmaceuticals BV, Nijmegen, The Netherlands)
Floris van Delft (Synaffix BV, Oss, The Netherlands)
Graham Cotton (Almac Discovery, Belfast, Northern Ireland, UK)
Estelle McLean (Almac Discovery, Belfast, Northern Ireland, UK)
Vijay Chudasama (University College London, London, UK)
Calise Bahou (University College London, London, UK)
Eugen Merkul (LinXis BV, Amsterdam, The Netherlands)

Conference Scope and Topics:

  • Novel ADC targets/ADC target discovery/target disease indications (including non-cancer targets)
  • Novel payloads/modes of action (beyond tubulin binders)
  • Biological components (antibody & antibody-like formats; molecularly defined conjugation sites)
  • Chemical components: Linker/payload combinations; optimization of linker chemistry; cleavable linkers
  • Next generation ADCs (site-specifically conjugated, including enzymatic conjugation
  • Immunotoxins
  • Chemistry approaches: mediating high toxicity of new warheads currently in use
  • Chemical modifications of ADC structure and linkers
  • Improving the therapeutic index – toxicity reduction efforts avoiding efficacy reduction
  • Other carrier/delivery possibilities beyond antibodies and bispecific antibodies (nanoparticles, peptides, aptamers, hormones and their analogues, small molecules, liposomes, vitamins)
  • Manufacturing/Regulatory issues
  • Process development (robustness, scalability)
  • Clinical stage ADCs/ongoing clinical trials, clinical translation

ATDC 2019 Delegates

Login details will be supplied after you have registered for the event.

ATDC 2019 Sponsors

  • Catalent Biologics
  • Genovis
  • Cancer Targeting Solutions Consulting
  • ImmunoGen
  • OncoZine
  • ADC Review
  • LinXis
  • Sutro Biopharma
  • Almac Discovery
  • NBE Therapeutics
  • Aldevron
  • Genentech
  • Lonza

ATDC 2019 Downloads

ATDC 2019 Leaflet

ATDC 2019 Mailing List

E-mail Address
What is 3+2-1?